Smart Communications Simplifies Digital Archiving with Launch of SmartHUB™
17.6.2025 15:02:00 CEST | Business Wire | Press Release
Smart Communications,the leading provider for cloud-based enterprise customer communications, today announced the availability of SmartHUB, a new cloud-native digital archiving solution designed to help businesses manage high-volume communications at scale, provide easy access to critical archived data, and ensure compliance with evolving industry regulations, regardless of sector or region. SmartHUB is built on the proven technology acquired through Smart Communications’ April 2025 acquisition of Joisto, a leading digital archiving provider, and is now fully integrated into the Conversation Cloud™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617555406/en/
As businesses face growing data volumes, disconnected systems, and increasingly complex regulations, SmartHUB tackles these inefficiencies head-on. It enables seamless integration across systems and reduces IT burden and operational complexity, all while maintaining a strong focus on data security and compliance. With SmartHUB, businesses can trust that their data is securely managed and compliant with evolving regulations, ensuring both operational efficiency and peace of mind.
“By harnessing the power of cloud-native technology, we’re enabling our customers to stay ahead of an increasingly complex and fast-moving regulatory environment, while significantly reducing operational risk, simplifying system complexity, and strengthening data security,” said Leigh Segall, CEO at Smart Communications. “Just as we’ve redefined how enterprises manage customer communications and forms with modern, scalable solutions, we’re now doing the same for archiving—giving organizations a trusted path to move away from legacy systems. SmartHUB will fundamentally transform how organizations store, access, and protect their most critical communications and customer data assets, unlocking new value that was previously out of reach.”
Designed on AWS and purpose-built for regulatory environments, SmartHUB also helps organizations proactively manage their legal obligations by offering immutable, audit-ready storage, comprehensive audit trails, and retention rule configurations across multiple jurisdictions with technology that meets requirements for GDPR, ISO 14641, and WCAG 2.1 Level AA. The platform simplifies the complexity of compliance across geographies, allowing enterprises to automate retention policies, track document lineage, and rapidly respond to audits or litigation.
“SmartHUB expands the Smart Communications value proposition significantly, offering a more complete end-to-end platform for managing the entire customer conversation, from creation and delivery to long-term, compliant storage and retrieval. It differentiates Smart Communications in a competitive market by directly addressing a critical pain point for its core customer base,” said Jim Lundy, Founder and CEO at Aragon Research.
SmartHUB uses flexible APIs and enterprise-level configuration management to integrate across other ERP, CRM, and HR systems, embedding compliance directly into core business workflows. This enables it to connect teams across customer service, IT, sales, claims handlers and more, reducing common friction points and latency when dealing with a customer service case, on-demand portal requests from end customers, or even to support compliance or litigation requests.
“SmartHUB was designed to meet the demands of today’s communications landscape—where speed, security, and compliance are non-negotiable. With ingestion speeds of up to one million documents per hour and a cloud-native architecture, it eliminates the need for hardware while ensuring scalable, always-on access to critical data,” said Simon Tindal, CTO at Smart Communications. “As AI transforms how archived communications are used—whether for real-time decisioning, self-service, or context-rich customer interactions—SmartHUB ensures that high-volume data is not just stored, but instantly retrievable and audit-ready.”
SmartHUB has proven success across financial services, insurance, telco, and utilities, making it an ideal fit for any organization with high customer communications volumes, complex compliance needs, or large customer service operations. As part of the Conversation Cloud, it simplifies archiving at scale and unlocks seamless integration with SmartCOMM™ and SmartIQ™,offering teams a single, secure place to create, manage, and access all critical customer interactions.
To see how SmartHUB transforms archiving into an advantage, visit https://www.smartcommunications.com/products/smarthub/.
About Smart Communications:
Smart Communications is the trusted choice for regulated enterprises looking to modernize complex processes and connect with customers in the moments that matter most. Its Conversation Cloud™ platform powers frictionless, compliant, digital-first experiences through omnichannel communications, intelligent data capture, and secure digital archival. More than 650 enterprises worldwide—including Zurich Insurance, Priority Health, The Pacific Financial Group, and The Bancorp—rely on Smart Communications to reduce compliance risk, boost operational efficiency, lower costs, and fast-track digital transformation that fuels business growth and elevates the customer experience. With more than 30 pre-built connectors, Smart Communications’ cloud-native platform integrates effortlessly with the world’s most trusted enterprise systems including Salesforce, Guidewire, DuckCreek, OneSpan, and Pega, enabling more than 60 billion mission-critical customer conversations globally, and driving faster time to value.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617555406/en/
Contacts
For media inquiries, contact:
Red Lorry Yellow Lorry for Smart Communications
smartcommunications@rlyl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom